Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimir: 2151-8017
ISSN En Línea: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2014008368
pages 219-239

Bacterial Toxins in Cancer Immunotherapy

Irena Adkins
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Sadilkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
Lenka Palova-Jelinkova
Sotio a.s., Prague, Czech Republic; and Department of Immunology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic

SINOPSIS

Bacterial protein toxins perfected through evolution in pathogenic bacteria play an important role in infectious diseases and share the ability to target various intracellular proteins to modulate host immune responses. Several bacterial toxins and their nontoxic mutants have been intensively studied over the past decades to harness their abilities to enter host cells and deliver drugs for a direct elimination of cancer cells, to carry antigenic epitopes to stimulate adaptive T cell responses, and to boost immunity as adjuvants. Some of these toxins may be utilized in the diagnostics of cancer. Whereas the immunotherapeutic potential of some bacterial toxins is currently being evaluated in various phases of clinical cancer trials, the medical use of others needs to be further established. The major achievement in toxin-targeted immunotherapy is a derivative of lipopolysaccharide monophosphoryl lipid A, muramyl dipeptide derivative Mifamurtide, and Corynebacterium diphtheriae diphtheria toxin-based immunotoxin denileukin diftitox. However, some limitations of the use of bacterial toxins in human immunotherapy remain to be overcome.


Articles with similar content:

Medicinal Value of Turkey Tail Fungus Trametes versicolor (L.:Fr.) Pilat (Aphyllophoromycetideae)
International Journal of Medicinal Mushrooms, Vol.7, 2005, issue 3
Christopher Hobbs
Immunocytokines for Cancer Therapy
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 1-2
Dario Neri, Philipp Probst
Mycobacterium Biofilms: Factors Involved in Development, Dispersal, and Therapeutic Strategies Against Biofilm-Relevant Pathogens
Critical Reviews™ in Eukaryotic Gene Expression, Vol.24, 2014, issue 3
Jianping Xie, Wanyan Deng, Xiaohong Xiang, Minqiang Liu
Dendritic Cells in Cancer Immunotherapy
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Matthias Gunzer, Stephan Grabbe
New Approaches to Antigen Delivery
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.17, 2000, issue 3
David FitzGerald, Randall J. Mrsny